Cerenovus Embotrap Devices Evaluated in EXCELLENT Registry of Mechanical Thrombectomy for Acute Ischemic Stroke

November 18, 2022—Cerenovus, Inc., part of Johnson & Johnson MedTech, announced primary outcomes from the real-world EXCELLENT Registry focused on mechanical thrombectomy with the company’s Embotrap II or Embotrap III revascularization devices as a first-line therapy.

Launched by the company in 2018, the EXCELLENT registry is a large, international, multicenter cohort of “all-comers” patients featuring a wide range of stroke cases, including patients who in the past have not been considered good thrombectomy candidates. The acute ischemic stroke registry is collecting patient data, imaging, and clots on a per-pass basis with independent adjudication by an imaging core lab and clinical events committee.

The findings were presented at the Society of Vascular and Interventional Neurology (SVIN) annual meeting held November 16-19 in Los Angeles, California.

According to Cerenovus, the EXCELLENT registry aims to characterize the Embotrap device at multiple hospitals using the technique of choice to reflect current practice patterns. Also, investigators will evaluate the clots retrieved to identify the potential impact different clot compositions can have on patient outcomes. Data presented at SVIN were collected from 2018 to presentin 1,000 ischemic stroke patients from 36 sites worldwide.

As summarized in the company’s press release, the primary results include the following:

• Final successful reperfusion of 94.5% achieved with mixed techniques
• > 50% of completed procedures performed with a single pass of Embotrap
• First pass substantial reperfusion of 63% and near-complete reperfusion of 38.1%
• Good to ideal clinical outcomes in 46.8% of patients
• Symptomatic complications of 1.6% and 0.6% in cases with a single pass of Embotrap

The company advised that the EXCELLENT registry is being expanded to 1,000 additional stroke patients and will include new sites in China and Japan. The expanded study will also include the Cerenovus large bore catheter/Embovac aspiration catheter to examine the impact of direct aspiration as a first-line treatment and enable investigators to study clots retrieved through both direction aspiration and stent retrievers.